Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02823028 · ClinicalTrials.gov registry record · Phase 2
Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)
A Phase 2 study of Smoking Cessation, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 980
- Enrollment target
- 2
- Study locations
NCT02823028: Completed Phase 2 study of Smoking Cessation, sponsored by University of California, Irvine.
NCT02823028 is a Phase 2 study of Smoking Cessation that has completed, run by University of California, Irvine. The registered enrollment target is 980 participants, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (109% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02823028, a Phase 2 study of Smoking Cessation, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 980 participants
- Enrollment target
- 2
- Study locations
Study Summary
Tweet2Quit is an innovative smoking cessation intervention that combines real-time online peer-to-peer support with auto messaging. In a three-group randomized controlled trial, the investigators will compare: 1) usual care, 2) Tweet2Quit-coed, and 3) Tweet2Quit-Women only.
Primary Outcome
Percentage of participants who reported no use of tobacco products by answering the questions: 'How many cigarettes have you smoked', 'How many other tobacco products have you used', and 'How many times have you used e-cigs' since the quit date (assessed at 1, 3 and 6 months post quit date) confirmed by salivary cotinine measurement (assessed at 3 and 6 months post quit date). Note: We will apply the Russell Standard for abstinence, allowing 5 or fewer instances of tobacco use over 6 months. In
Conditions Studied
Interventions
- DRUG NRT
- BEHAVIORAL Web Guide
- BEHAVIORAL Tweet2Quit
Study Locations (2)
California
- University of California, Irvine - Paul Merage School of Business - Irvine
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 980 participants |
| Start Date | 2016-10 |
| Est. Completion | 2022-09 |
| Phase | Phase 2 |
What the finished NCT02823028 record still lists
NCT02823028 is an interventional study that assigns participants to a tested intervention. The registered 980 participants enrollment target is mid-sized for trials with a published cap, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (109% higher).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which NRT is the first listed.
NCT02823028 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02823028 about?
NCT02823028 is a clinical study titled "Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)". Tweet2Quit is an innovative smoking cessation intervention that combines real-time online peer-to-peer support with auto messaging. In a three-group randomized controlled trial, the investigators will compare: 1) usual care, 2) Tweet2Quit-coed, and 3) Tweet2Quit-Women only.
What is the current status of trial NCT02823028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 980 participants. The study started on 2016-10. Estimated completion is 2022-09.
What conditions does trial NCT02823028 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT02823028?
The interventions under investigation include: NRT (DRUG), Web Guide (BEHAVIORAL), Tweet2Quit (BEHAVIORAL).
Who is sponsoring clinical trial NCT02823028?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02823028 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02823028's enrollment target sits among peer trials
980 25th of 188 higher than 164 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06337097 · 980 participants · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
- NCT07070232 · 980 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- NCT07184931 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- NCT07184996 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia